BridgeLine Translational Partners
Strategy Built to Survive Diligence and Accelerate the Path to the Clinic
Most preclinical plans are built by career consultants who have never filed an IND or sat across the table in a diligence review. BridgeLine is different. We build development programs that hold up in board meetings, in investor diligence, and in regulatory submissions, because we have been on both sides.
Complimentary | 30 minutes
What We Do
Three Pillars of Diligence-Grade Strategy
Each pillar addresses a distinct strategic question. Every pillar has a core engagement and its own Strategy Diagnostic entry point.
Preclinical & Nonclinical Strategy
Cut months off your path to IND by building a preclinical program backward from the milestones that actually drive value. BridgeLine specifies every study, model, and endpoint so your plan answers the questions investors, regulators, and partners will ask.
Core Engagement
Preclinical Roadmap
2-4 weeks
Target & Indication Strategy
Make sure your next $2M goes to the program with the strongest case. BridgeLine scores your targets and indications against scientific rationale, competitive landscape, commercial viability, and development cost, then gives you a clear GO/NO-GO.
Core Engagement
Target & Indication Evaluation
2-4 weeks
Investor & Partner Readiness
Strengthen your story so you walk into every conversation with confidence. BridgeLine runs a live mock diligence session, reviews your data, narrative, and positioning and works with you to strengthen each one.
Core Engagement
Diligence Readiness Package
2-4 weeks
| Study | Model + Rationale | Timeline | Budget |
|---|---|---|---|
| Efficacy POC | KO Mouse (target homology validated) | 12 wks | $85K |
| Biodistribution | NHP (FDA precedent for vector class) | 16 wks | $280K |
| 28-Day GLP Tox | Rat + NHP (ICH S6/M3 aligned) | 24 wks | $450K |
What Your Deliverables Look Like
Deliverables built to drive real decisions, not sit in a folder.
Every deliverable is structured for immediate use. Visual timelines, budget tables, risk assessments, and executive summaries. No translation layer required.
What makes it diligence-grade: every study has predefined success criteria and go/no-go gates. Budget estimates are quarterly, not annual lump sums. Risk registers have specific mitigations, not generic "regulatory risk" bullets. The plan answers the 10 questions a pharma BD team will ask in the first diligence call, because we have been the person asking them.
The Process
Four Steps from First Call to Finished Plan
Every engagement follows the same structured path: assess, diagnose, build, support.
Strategy Call
Share your program, stage, and the decisions keeping you up at night. BridgeLine assesses the situation and recommends whether to start with a Strategy Diagnostic or move directly into a core engagement. Complimentary, 30 minutes.
Strategy Diagnostic
A broad assessment across your most pressing dimension: preclinical strategy, target & indication strategy, or investor & partner readiness. Scored findings, gap analysis, and prioritized recommendations delivered in 1-2 weeks.
Core Engagement
Preclinical Roadmap, Diligence Readiness Package, or Target & Indication Evaluation. Each delivers outputs you can put in front of your board, investors, or partners: visual timelines, budget tables, risk assessments, and executive summaries.
Ongoing Support
Advisory or fractional leadership to carry the plan through execution. Strategy calls, protocol review, CRO oversight, board preparation, and senior judgment on call as your program advances through milestones.
Built by Someone Who's Been on Both Sides
We design programs to pass the same scrutiny we applied from the buy side.
When I evaluated gene therapy companies at Sarepta, the most common gap was not bad data. It was missing data: studies that were never run, endpoints that did not match what regulators would expect, and timelines that assumed everything would go right. That experience shapes every plan I build now. I design programs to answer the questions an acquirer's diligence team actually asks, because I was the one asking them.
Before that, I built IND-enabling programs as an operator at Spark Therapeutics (Roche) and StrideBio, where I learned what it takes to move a program from discovery data to a regulatory submission that holds up. Earlier career in process chemistry at Cephalon (now Teva) and academic research at the NIH Vaccine Research Center and University of Pennsylvania.
What This Looks Like in Practice
Anonymized engagement patterns from real programs.
Preclinical Roadmap
Gene Therapy, Rare Kidney Disease
The team had promising discovery data and needed a structured path from there to IND. BridgeLine built a staged roadmap with study-level specifications, go/no-go gates, and CRO-ready protocols that cut 14 months off the projected path to IND and saved an estimated $1.2M in misaligned studies.
Read the full case studyTarget & Indication Evaluation
RNA Therapeutics Platform, 30+ Indications
30+ potential indications, no structured way to choose. BridgeLine built a multi-dimensional scoring framework that narrowed 30+ candidates to the top 3 based on scientific rationale, competitive positioning, regulatory feasibility, and commercial viability. The framework became the company's ongoing pipeline decision tool.
Read the full case studyOpen Access
We publish the tools and resources we wish existed when we were building programs.
68 translational models with IND package recommendations for every modality. 650+ curated industry links. Conference directories. Regional ecosystem guides. All free, all ungated, because the best way to demonstrate expertise is to give it away.
Who BridgeLine Works With
Biotech companies building development programs from target evaluation through IND and into early clinical development, across one program or an entire pipeline.
What Clients and Colleagues Say
From leaders at Parallel Bio, Lilly, Bound Therapeutics, Sarepta Therapeutics, and Saturnus Bio.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Frequently Asked Questions
How engagements work, what BridgeLine delivers, and what to expect.
The BridgeLine Brief
Strategy breakdowns, deal analysis, and drug development insights you won't find anywhere else. Written from inside the industry by someone who has built programs and evaluated companies firsthand. Plus updates when we publish new guides, tools, and resources for early-stage biotech teams.
By subscribing you agree to our Privacy Policy.
Ready to Build Strategy That Survives Real Review?
Book a complimentary Strategy Call. 30 minutes to assess your program, see where you stand, and recommend the right starting point.
Book a Strategy CallComplimentary · 30 minutes · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com